GlassScriptPhysician profile
John A Limburg
NPI 1013900604
$5,645.86
in general payments reported to CMS, 2019-2025
36 companies · $748 in 2025
The $748 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $764 · 2021: $322 · 2022: $580 · 2023: $582 · 2024: $868 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,197.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $955.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $676.78 | 2021-2025 | |
| Novo Nordisk INC | $662.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $394.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $318.40 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.69 | 2019-2025 | Jardiance |
| Amgen INC. | $278.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $264.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $253.87 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Allergan, INC. | $172.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.96 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $126.69 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $111.58 | 2019-2023 | Veozah |
| Abbott Laboratories | $110.31 | 2022-2025 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $98.34 | 2019-2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Limburg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.